Navigation Links
EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
Date:9/19/2007

MANCHESTER, England, September 20 /PRNewswire-FirstCall/ -- EpiStem (LSE: EHP) announced today that it has completed the first year of mucositis efficacy-testing services for potential biodefense drugs, and are about to embark upon an extensive drug screening programme over the coming year.

The National Institutes of Health (NIH) Medical Countermeasures against Radiological and Nuclear Threats (MCART) programme leads the U.S. effort to develop treatments for radiation sickness following a nuclear terrorist attack. EpiStem is a major provider of services to identify novel drugs that can improve the repair of the gastrointestinal (GI) tract following exposure to irradiation. There are currently no medications approved by the FDA to treat this syndrome. EpiStem is an established provider of similar GI assays for oncology supportive care. These assays provide quantitative and mechanistic data to assess the efficacy of novel drug candidates, enabling companies to make informed decisions regarding the progression of their preclinical pipeline.

Dr Tom MacVittie, who co-ordinates the programme at the University of Maryland School of Medicine said: "Gastrointestinal acute radiation syndrome (GI-ARS) is a massive, currently untreatable, problem following high-dose radiation exposure. Agents that mitigate these effects could reduce sickness and hopefully prevent fatalities. The tests performed by EpiStem are also likely to identify agents with oncology supportive care applications - agents that will reduce the severe ulceration and diarrhoea (mucositis) experienced by patients during radio- and chemo-therapy".

Dr Catherine Booth, head of EpiStem's contract research division commented: "After completion of a series of validatory assays, initial studies on first three test drugs have successfully been completed, with approx 10 more with an estimated value of US$0.75m revenue for the Company in the pipeline for the coming year. The programme is forecast to extend over the next 3 years. EpiStem is also now working to gain GLP compliance for the next phase of the project, in order to help the consortium develop drugs for FDA approval in future years".

Other members of the Consortium include the University of Maryland, Baltimore, the University of Illinois at Chicago, Indiana University at Indianapolis, the Armed Forces Radiobiology Research Institute at Bethesda, Fast Track Drugs and Biologics LLC, Aotech, LLC, and Information Management Consultants, Inc.

Additional Information

EpiStem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. EpiStem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. EpiStem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

EpiStem operates two distinct business divisions, Contract Research Services and Novel Therapies.

Contract Research Services

Contract Research Services provides specialised preclinical efficacy testing primarily for drug development companies on a fee for service basis. This division on a standalone basis is cash generative and profitable with a five-year track record of providing testing services to over 72 international company clients primarily in Europe and the United States.

Novel Therapies

Novel Therapies is focused on developing its own innovative therapeutics and diagnostic biomarkers. Through its discovery platform, Novel Therapies has identified 250 potential drug candidates, of which a subset will undergo further evaluation as stem cell regulators for the Group's emerging drug development pipeline. Novel Therapies is also developing its clinical diagnostic biomarker technology.

Combined Business Model

The Group is exploiting its combined business model to advance its own therapeutic candidates to late preclinical stage development. The business model integrates the discovery efforts of Novel Therapies with the efficacy testing assays of its Contract Research Services Division, to identify and characterise new drug candidates. Revenues generated by Contract Research Services will assist in offsetting Novel Therapies' investment requirements for the discovery and development of therapeutics. In February 2007, EpiStem licensed its first drug candidate to a clinical development company. With the validation of the Novel Therapies discovery platform and the achievement of discovery milestones, the Directors believe that additional licensing partnerships will be forthcoming for therapeutics, diagnostics and cosmeceuticals starting in 2008.

For more information please contact:

Matthew Walls

Chief Executive Officer

EpiStem Ltd

+44-(0)-161-606-7258

Mike Wort, Anna Dunphy

MC Bio-Communications Limited

+44-(0)-20-7744-7711

Thilo Hoffmann

Landsbanki Securities (UK) Limited

+44-(0)-20-7426-9000


'/>"/>
SOURCE Epistem Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
2. Potawatomis complete acquisition of tech firm
3. Sonic Foundry completes $11.25M stock offer
4. Orion Energy completes $5M capital round
5. RedPrairie completes MARC acquisition
6. Metavante completes purchase of check processing firm
7. GE completes $1.2 billion acquisition
8. M & Is Metavante completes Brasfield Corp. acquisition
9. Berbee Data Centers complete audit, certification
10. Metavante completes GHR Systems acquisition
11. Metavante completes TREEV acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):